News 2024-10-10
Connect with Porton J-STAR at AAPS PharmSci 360 2024 @ Booth 2431
The AAPS PharmSci 360, held from October 20-23, 2024, is an eminent event in the pharmaceutical industry, renowned for its convergence of key players, thought leaders, and innovative companies from across the globe. This year, Porton J-STAR invites you to connect with us at Booth 2431, where we will be exhibiting our end-to-end global CDMO service capabilities across both drug substance and drug product development and manufacturing, and the differentiated advantages these services offer to customers.
We employ advanced technologies and methodologies in our CDMO services. Our participation at AAPS PharmSci 360 reflects our dedication to innovation and excellence. With over 10,000 professionals and numerous exhibitors from various segments of the pharmaceutical industry, this conference is a premier platform for networking, collaboration, and showcasing cutting-edge advancements. It provides an unparalleled opportunity for us to engage with industry peers, explore potential partnerships, and drive forward the growth and innovation of the pharmaceutical sector.
As one of the world's leading CDMO companies, Porton J-STAR will be attending the event. Our expert speakers will deliver advanced technical insights and industry perspectives, offering attendees a deep dive into the latest developments.
For onsite meeting appointments, please contact:business@portonpharma.com.
Others
More
News 2026-10-22
Simplifying Synthesis with Radical Cross-Coupling: Prof. Phil S. Baran of Scripps Research Lectures at Porton
The event was hosted by Dr. Yongli Zhong, CSO, and attended by Mr. Oliver Ju, Chairman and CEO; Mr. Yunxing Yin, VP and Head of the Small Molecule Platform, and more than 200 R&D and technical staff.

News 2026-10-16
Porton Achieves Third-Party Verification for Its First Commercial Product LCA and PCF Study
Conducted in accordance with ISO 14040:2006 and ISO 14044:2006 (Life Cycle Assessment) and ISO 14067:2018 (Product Carbon Footprint) standards, the study employs a cradle-to-gate system boundary, marking the formal extension of Porton's ESG management from the organizational level to the product level.